Correlation of myocardial performance index and serum ferritin levels in children with beta thalassemia major

Jagadisha Siddammanahalli, Mallesh Kariyappa, Premalatha Ramaswamy, Shwetha NH, Ganga Kusuma


Background: Cardiac complications are the major causes of mortality and morbidity in β Thalassemia major. Early recognition of cardiac iron overload by 2D and Doppler echocardiography which is economical guides early intervention and hence minimise morbidity and mortality. The objective of the study was assessment of myocardial performance index (MPI) and serum ferritin (SF) in children with β-Thalassemia and to establish relation of myocardial performance index in to serum ferritin level and age.

Methods: A Cross -sectional descriptive analytical study including 34 patients in the age group 3 years to 17 years with β-thalassemia on regular blood transfusion were included in the study. M-mode, 2D and Doppler echocardiography is used for analysis of isovolumic relaxation time (IVRT), isovolumic contraction time (IVCT), ejection time (ET) and MPI. SF was measured by ELISA.

Results: Mean age was 9.21(+/-3.9) years. SF ranged from 365 to 18826µg/L. MPI varied from 0.35 to 0.62. Similarly IVRT varied from 35ms to 74 ms (60.26+/-12.36ms), IVCT from 36 to 75ms, ET from 108 to 280ms. MPI was 0.39±0.04 (Mean±SD) at SF≤1000 µg/L against 0.49±0.04 at SF of 1000 µg/L to 2499 µg/L. Rate of increase of MPI was maximum from SF 582 µg/L to 1962µg/L.

Conclusions: Mean MPI is abnormal at SF levels more than 1000 µg/L. Although MPI value is within the normal limit for the age at SF levels less than 1000 µg/L, MPI starts increasing with increasing SF from as low as 582 µg/L. Serial evaluation could give better information even if myocardial performance index falls within normal range for the age.


Myocardial performance index, β Thalassemia major, Serum ferritin, Cardiac MRI

Full Text:



Olivieri NF, Brittenham GM. Iron-chelating therapy andthe treatment of thalassemia. Blood. 1997;89:739-61.

Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127:348-55.

Noetzli LJ, Carson SM, Nord AS, Coates TD, Wood JC. Longitudinal analysis of heart and liver iron in thalassemiamajor. Blood. 2008;112:2973-8.

Brittenham GM. Iron-chelating therapy for transfusionaliron overload. N Engl J Med. 2011;364:146-56.

Shahmohammadi A, Davari PN, Aarabi Y, Meraji M, Tabib A. Echocardiographic Assessment of Cardiac Involvement in Patients with Thalassemia Major: Evidence of Abnormal Relaxation Pattern of the Left Ventricle in Children and Young Patients. Iranian Heart Journal. 2006;7(1):31-6.

Kolnagou A, Economides C, Eracleous E, Kontoghiorghes GJ. Low serum ferritin levels are misleading for detecting cardiac iron overload and increase the risk of cardiomyopathy in thalassemia patients. The importance of cardiac iron overload monitoring using magnetic resonance imaging T2and T2*. Hemoglobin. 2006;30:219-27.

Piperno A. Classification and diagnosis of iron overload. Haematologica. 1998;83:447-55.

Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Fei¬genbaum H, et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. J Am Soc Echo. 1989;2:358-67.

Heidi M, Connoly, Jae K. Echocardiography,In Braunwald’s heart disease,a textbook of cardiovascular medicine, 8th edition, Philadelphia, Saunders. 2008:227-32.

Bruch C, Schmermund A, Marin, M. Katz D, Bartel T, Schaar J, et al. Tei-Index in patients with mild-to-moderate congestive heart failure. Eur Heart J. 2000;21:1888-95.

Spencer KT, Kirkpatrick JN, Mor-Avi V, Decara JM, Lang RM. Age dependency of the Tei Index of myocardial performance. J Am Soc Echocardiogr. 2004;17:350-2.

Tei C, Ling LH, Hodge DO, Bailey KR, Oh JK, Rodeheffer RJ, et al. New index of combined systolic and diastolic myocardial perfor¬mance: a simple and reproducible measure of cardiac function – a study in normals and dilated cardiomyopathy. J Cardiol. 1995;26:357-66.

Rohani A, Akbari V, Moradipoor M, Akbartabar M. Prevalence of Heart Failure in the Cases of Beta-thalassemia Major; Two Years Follow-Up. J of Cardio-Thoracic medicine. 2013;1(1):16-9.

Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection of di¬agnostic tests and procedures. Ann Int Med. 1981;94:557-92.

Zeuner D, Ades AE, Karnon J, Brown J, Dezateux C, Anionwu EN. Antenatal and neonatal haemoglobinopathy screening in the UK: review and economic analysis. Health Technol Assess. 1999;3:1-186.

Abbas AA, Najeb B, Abdulhussein A, Jassim JH, Falih MA, Jubiaer H, et al. Echocardiographic Parameters of Left Ventricle Systolic and Diastolic Function in Patients with β-Thalassemia Major. The Iraqi Postgraduate Medical Journal. 2012;11(4):562-8.

Angeja, BG, Grossman W. Diastolic dysfunction and congestive heart failure. Circulation. 2003;107:659-63.

Olson LJ. Cardiac iron deposition in idiopathic hemochromatosis. J Am Coll Cardiology. 1987;10:1239-43.

Olivieri NF. The beta-thalassemias. N Engl J Med. 1999;341:99-109.

Anderson LJ, Holden S, Davis B. Cardiovascular T2- star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001;22:2171-9.

Wood JC, Enriquez C, Ghugre Nl. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci. 2005;1054:386-95.

Letsky EA, Miller F, Worwood ML. Serum ferritin in children with thalassaemia regularly transfused. J Clin Pathol. 1974;27:652-5.